Influenza pathogenesis: Lessons learned from animal studies with H5N1, H1N1 Spanish and pandemic H1N1 2009 influenza

Critical Care Medicine

Volumn 38, Issue SUPPL. 4, 2010, Pages

  Meunier, Isabelle ^a,b   Pillet, Stéphane ^a,b   Simonsen, J Neil ^a,b   Von Messling, Veronika ^a,b   DrMedVet, ^a,b  

^a INRS INSTITUT ARMAND FRAPPIER   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

Animal models; Highly pathogenic influenza; Pathogenesis treatment approaches

Indexed keywords

ALPHA INTERFERON; AMANTADINE; ANTIVIRUS AGENT; CHLOROQUINE; CORTICOSTEROID; ENZYME INHIBITOR; FAVIPIRAVIR; FLUDASE; HYBRID PROTEIN; INTERFERON; INTERFERON INDUCING AGENT; OSELTAMIVIR; PERAMIVIR; PROTEIN M2; RIBAVIRIN; RIMANTADINE; SIALIDASE INHIBITOR; SMALL INTERFERING RNA; TARIBAVIRIN; TRIAMCINOLONE; UNCLASSIFIED DRUG; VIRUS SIALIDASE; ZANAMIVIR;

AVIAN INFLUENZA; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOTHERAPY; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; INNATE IMMUNITY; NONHUMAN; PANDEMIC; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY FUNCTION; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; SINGLE DRUG DOSE; SPANISH INFLUENZA; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION;

EID: 77950236839     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181c8b4d5     Document Type: Article

References (129)

1. Neumann G, Noda T, Kawaoka Y: Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009; 459: 931-939
2. Tran TH, Nguyen TL, Nguyen TD, et al: Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 2004, 350: 1179-1188
3. Yuen KY, Chan PK, Peiris M, et al: Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998; 351: 467-471
4. de Jong MD, Simmons CP, Thanh TT, et al: Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12: 1203-1207
5. Cheung CY, Poon LL, Lau AS, et al: Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: A mechanism for the unusual severity of human disease? Lancet 2002; 360(9348): 1831-1837
6. Baskin CR, Bielefeldt-Ohmann H, Tumpey TM, et al: Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci U S A 2009; 106: 3455-3460
7. Lu X, Tumpey TM, Morken T, et al: A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol 1999; 73: 5903-5911
8. Dybing JK, Schultz-Cherry S, Swayne DE, et al: Distinct pathogenesis of hong kong-origin H5N1 viruses in mice compared to that of other highly pathogenic H5 avian influenza viruses. J Virol 2000; 74: 1443-1450
9. Govorkova EA, Rehg JE, Krauss S, et al: Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J Virol 2005; 79: 2191-2198
10. Maines TR, Lu XH, Erb SM, et al: Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol 2005; 79: 11788-11800
11. Rimmelzwaan GF, Kuiken T, van Amerongen G, et al: Pathogenesis of influenza A (H5N1) virus infection in a primate model. J Virol 2001; 75: 6687-6691
12. Zitzow LA, Rowe T, Morken T, et al: Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J Virol 2002; 76: 4420-4429
13. Lipatov AS, Kwon YK, Pantin-Jackwood MJ, et al: Pathogenesis of H5N1 influenza virus infections in mice and ferret models differs according to respiratory tract or digestive system exposure. J Infect Dis 2009; 199: 717-725
14. Lipatov AS, Kwon YK, Sarmento LV, et al: Domestic pigs have low susceptibility to H5N1 highly pathogenic avian influenza viruses. PLoS Pathog 2008; 4: e1000102
15. Kash JC, Tumpey TM, Proll SC, et al: Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature 2006; 443: 578-581
16. Cameron CM, Cameron MJ, BermejoMartin JF, et al: Gene expression analysis of host innate immune responses during lethal H5N1 infection in ferrets. J Virol 2008; 82: 11308-11317
17. Perrone LA, Plowden JK, Garcia-Sastre A, et al: H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathol 2008; 4: e1000115
18. Szretter KJ, Gangappa S, Lu X, et al: Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice. J Virol 2007; 81: 2736-2744
19. Tumpey TM, Lu X, Morken T, et al: Depletion of lymphocytes and diminished cytokine production in mice infected with a highly virulent influenza A (H5N1) virus isolated from humans. J Virol 2000; 74: 6105-6116
20. Wintemitz MC, Wason IM, McNamara FP: The Pathology of Influenza. New Haven, CT, Yale University Press, 1920
21. Taubenberger JK, Morens DM: 1918 Influenza: The mother of all pandemics. Emerg Infect Dis 2006; 12: 15-22
22. Reid AH, Fanning TG, Hultin JV, et al: Origin and evolution of the 1918 "Spanish" influenza virus hemagglutinin gene. Proc Natl Acad Sci U S A 1999; 96: 1651-1656
23. Taubenberger JK, Reid AH, Krafft AE, et al: Initial genetic characterization of the 1918 "Spanish" influenza virus. Science 1997; 275: 1793-1796
24. Tumpey TM, Basier CF, Aguilar PV, et al: Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 2005; 310: 77-80
25. Watanabe T, Watanabe S, Shinya K, et al: Viral RNA polymerase complex promotes optimal growth of 1918 virus in the lower respiratory tract of ferrets. Proc Natl Acad Sci U S A 2009; 106: 588-592
26. Kobasa D, Jones SM, Shinya K, et al: Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 2007; 445: 319-323
27. Weingartl HM, Albrecht RA, Lager KM, et al: Experimental infection of pigs with the human 1918 pandemic influenza virus. J Virol 2009; 83: 4287-4296
28. Van Hoeven N, Belser JA, Szretter KJ, et al: Pathogenesis of 1918 pandemic and H5N1 influenza virus infections in a guinea pig model: antiviral potential of exogenous alpha interferon to reduce virus shedding. J Virol 2009; 83: 2851-2861
29. Enserink M: Pandemic influenza. Ferrets shed light on new virus's severity and spread. Science 2009; 325: 17
30. Maher JA, DeStefano J: The ferret: An animal model to study influenza virus. Lab Anim (NY) 2004; 33: 50-53
31. Tumpey TM, Maines TR, Van Hoeven N, et al: A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission. Science 2007; 315: 655-659
32. Tumpey TM, Garcia-Sastre A, Taubenberger JK, et al: Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: Functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. J Virol 2005; 79: 14933-14944
33. Dawood FS, Jain S, Finelli L, et al: Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360: 2605-2615
34. Munster VJ, de Wit E, van den Brand JM, et al: Pathogenesis and transmission of swineorigin 2009 A(H1N1) influenza virus in ferrets. Science 2009; 325: 481-483
35. Itoh Y, Shinya K, Kiso M, et al: In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009; 460: 1021-1025
36. Maines TR, Jayaraman A, Belser JA, et al: Transmission and pathogenesis of swineorigin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 2009; 325: 484-487
37. Hay AJ, Wolstenholme AJ, Skehel JJ, et al: The molecular basis of the specific antiinfluenza action of amantadine. EMBO J 1985; 4: 3021-3024
38. Dolin R, Reichman RC, Madore HP, et al: A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 1982; 307: 580-584
39. Hayden FG, Sperber SJ, Belshe RB, et al: Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother 1991; 35: 1741-1747
40. Reuman PD, Bernstein DI, Keefer MC, et al: Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A. Antiviral Res 1989; 11: 27-40
41. Younkin SW, Betts RF, Roth FK, et al: Reduction in fever and symptoms in young adults with influenza A/Brazil/78 H1N1 infection after treatment with aspirin or amantadine. Antimicrob Agents Chemother 1983; 23: 577-582
42. Hayden F: Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 2009; 48(Suppl 1): S3-S13
43. He G, Qiao J, Dong C, et al: Amantadineresistance among H5N1 avian influenza viruses isolated in Northern China. Antiviral Res 2008; 77: 72-76
44. Palese P, Tobita K, Ueda M, et al: Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 1974; 61: 397-410
45. Palese P, Compans RW: Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetyl-neuraminic acid (FANA): Mechanism of action. J Gen Virol 1976; 33: 159-163
46. Lowen AC, Palese P: Influenza virus transmission: Basic science and implications for the use of antiviral drugs during a pandemic. Infect Disord Drug Targets 2007; 7: 318-328
47. Kawai N, Ikematsu H, Iwaki N, et al: A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: A Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. Clin Infect Dis 2006; 43: 439-444
48. Govorkova EA, Ilyushina NA, Boltz DA, et al: Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother 2007; 51: 1414-1424
49. Stittelaar KJ, Tisdale M, van Amerongen G, et al: Evaluation of intravenous zanamivir against experimental influenza A (H5N1) virus infection in cynomolgus macaques. Antiviral Res 2008; 80: 225-228
50. Sweeny DJ, Lynch G, Bidgood AM, et al: Metabolism of the influenza neuraminidase inhibitor prodrug oseltamivir in the rat. Drug Metab Dispos 2000; 28: 737-741
51. Hurt AC, Ernest J, Deng YM, et al: Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res 2009; 83: 90-93
52. Lackenby A, Hungnes O, Dudman SG, et al: Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill 2008; 13: pii 8026
53. Dharan NJ, Gubareva LV, Meyer JJ, et al: Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009; 301: 1034-1041
54. Jonges M, van der Lubben IM, Dijkstra F, et al: Dynamics of antiviral-resistant influenza viruses in the Netherlands, 2005-2008. Antiviral Res 2009; 83: 290-297
55. Le QM, Kiso M, Someya K, et al: Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005; 437: 1108
56. CDC: Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxisNorth Carolina, 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 969-972
57. Leung TW, Tai AL, Cheng PK, et al: Detection of an oseltamivir-resistant pandemic influenza A/H1N1 virus in Hong Kong. J Clin Virol 2009; 46: 298-299
58. Hurt AC, Holien JK, Parker M, Kelso A, Barr IG: Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J Virol 2009; 83: 10366-10373
59. Beigel J, Bray M: Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res 2008; 78: 91-102
60. De Clercq E: Antiviral agents active against influenza A viruses. Nat Rev Drug Discov 2006; 5: 1015-1025
61. Berendt RF, Walker JS, Dominik JW, et al: Response of influenza virus-infected mice to selected doses of ribavirin administered intraperitoneally or by aerosol. Antimicrob Agents Chemother 1977; 11: 1069-1070
62. Scott GH, Stephen EL, Berendt RF: Activity of amantadine, rimantadine, and ribavirin against swine influenza in mice and squirrel monkeys. Antimicrob Agents Chemother 1978; 13: 284-288
63. Wilson SZ, Knight V, Wyde PR, et al: Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice. Antimicrob Agents Chemother 1980; 17: 642-648
64. Gilbert BE, McLeay MT: MegaRibavirin aerosol for the treatment of influenza A virus infections in mice. Antiviral Res 2008; 78: 223-229
65. Gilbert BE, Wyde PR: Pharmacokinetics of ribavirin aerosol in mice. Antimicrob Agents Chemother 1988; 32: 117-121
66. Smith CB, Charette RP, Fox JP, et al: Lack of effect of oral ribavirin in naturally occurring influenza A virus (H1N1) infection. J Infect Dis 1980; 141: 548-554
67. Knight V, Gilbert BE: Ribavirin aerosol treatment of influenza. Infect Dis Clin North Am 1987; 1: 441-457
68. Rodriguez WJ, Hall CB, Welliver R, et al: Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: A double-blind, multicenter, placebocontrolled trial. J Pediatr 1994; 125: 129-135
69. Hayden FG, Sable CA, Connor JD, et al: Intravenous ribavirin by constant infusion for serious influenza and Parainfluenzavirus infection. Antivir Ther 1996; 1: 51-56
70. Wu JZ, Walker H, Lau JY, et al: Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: Adenosine deaminase catalyzes two consecutive deamination reactions. Antimicrob Agents Chemother 2003; 47: 426-431
71. Sidwell RW, Bailey KW, Wong MH, et al: In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Res 2005; 68: 10-17
72. Pyre K, Berkhout B, van der Hoek L: Antiviral strategies against human coronaviruses. Infect Disord Drug Targets 2007; 7: 59-66
73. Yuki N, Nagaoka T, Nukui K, et al: Adding interferon to lamivudine enhances the early virologic response and reversion of the precore mutation in difficult-to-treat HBV infection. J Gastroenterol 2008; 43: 457-463
74. Keam SJ, Cvetkovic RS: Peginterferonalpha-2a (40 kD) plus ribavirin: a review of its use in the management of chronic hepatitis C mono-infection. Drugs 2008; 68: 1273-1317
75. Finter NB, Chapman S, Dowd P, et al: The use of interferon-alpha in virus infections. Drugs 1991; 42: 749-765
76. Isomura S, Ichikawa T, Miyazu M, et al: The preventive effect of human interferon-alpha on influenza infection; modification of clinical manifestations of influenza in children in a closed community. Biken J 1982; 25: 131-137
77. Philipotts RJ, Higgins PG, Willman JS, et al: Intranasal lymphoblastoid interferon ("Wellferon") prophylaxis against rhinovirus and influenza virus in volunteers. J Interferon Res 1984; 4: 535-541
78. Tumpey TM, Szretter KJ, Van Hoeven N, et al: The Mx1 gene protects mice against the pandemic 1918 and highly lethal human H5N1 influenza viruses. J Virol 2007; 81: 10818-10821
79. Kugel D, Kochs G, Obojes K, et al: Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets. J Virol 2009; 83: 3843-3851
80. Saravolac EG, Sabuda D, Crist C, et al: Immunoprophylactic strategies against respiratory influenza virus infection. Vaccine 2001; 19: 2227-2232
81. Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W, et al: Human disease from influenza A (H5N1), Thailand, 2004. Emerg Infect Dis 2005; 11: 201-209
82. Cinatl J Jr, Michaelis M, Doerr HW: The threat of avian influenza A (H5N1). Part III: Antiviral therapy. Med Microbiol Immunol 2007; 196: 203-212
83. Ottolini MG, Blanco JC, Eichelberger MC, et al: The cotton rat provides a useful smallanimal model for the study of influenza virus pathogenesis. J Gen Virol 2005; 86: 2823-2830
84. Salomon R, Hoffmann E, Webster RG: Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. Proc Natl Acad Sci U S A 2007; 104: 12479-12481
85. Legssyer R, Josse C, Piette J, et al: Changes in function of iron-loaded alveolar macrophages after in vivo administration of desferrioxamine and/or chloroquine. J Inorg Biochem 2003; 94: 36-42
86. Ohkuma S, Poole B: Cytoplasmic vacuolation of mouse peritoneal macrophages and the uptake into lysosomes of weakly basic substances. J Cell Biol 1981; 90: 656-664
87. Savarino A, Boelaert JR, Cassone A, et al: Effects of chloroquine on viral infections: an old drug against today's diseases?. Lancet Infect Dis 2003; 3: 722-727
88. Ooi EE, Chew JS, Loh JP, et al: In vitro inhibition of human influenza A virus replication by chloroquine. Virol J 2006; 3: 39
89. Vigerust DJ, McCullers JA: Chloroquine is effective against influenza A virus in vitro but not in vivo. Influenza Other Respi Viruses 2007; 1: 189-192
90. Jones JC, Turpin EA, Bultmann H, et al: Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells. J Virol 2006; 80: 11960-11967
91. Leikina E, Delanoe-Ayari H, Melikov K, et al: Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. Nat Immunol 2005; 6: 995-1001
92. Gambaryan AS, Tuzikov AB, Chinarev AA, et al: Polymeric inhibitor of influenza virus attachment protects mice from experimental influenza infection. Antiviral Res 2002; 55: 201-205
93. Belser JA, Lu X, Szretter KJ, et al: DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis 2007; 196: 1493-1499
94. Malakhov MP, Aschenbrenner LM, Smee DF, et al: Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 2006; 50: 1470-1479
95. Chan RW, Chan MC, Wong AC, et al: DAS181 Inhibits H5N1 Influenza virus Infection of Human Lung Tissues. Antimicrob Agents Chemother 2009; 53: 3935-3941
96. Zhirnov OP: High protection of animals lethally infected with influenza virus by aprotinin-rimantadine combination. J Med Virol 1987; 21: 161-167
97. Zhirnov OP, Kirzhner LS, Ovcharenko AV, et al: [Clinical effectiveness of aprotinin aerosol in influenza and parainfluenza]. Vestn Ross Akad Med Nauk 1996; 5: 26-31
98. Bantia S, Arnold CS, Parker CD, et al: Antiinfluenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res 2006; 69: 39-45
99. Boltz DA, Ilyushina NA, Arnold CS, et al: Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice. Antiviral Res 2008; 80: 150-157
100. Yun NE, Linde NS, Zacks MA, et al: Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). Virology 2008; 374: 198-209
101. Barroso L, Treanor J, Gubareva L, et al: Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir Ther 2005; 10: 901-910
102. Plotch SJ, Bouloy M, Ulmanen I, et al: A unique cap(m7GpppXm)-dependent influenza virion endonuclease cleaves capped RNAs to generate the primers that initiate viral RNA transcription. Cell 1981; 23: 847-858
103. Tisdale M, Ellis M, Klumpp K, et al: Inhibition of influenza virus transcription by 2′deoxy-2′-fluoroguanosine. Antimicrob Agents Chemother 1995; 39: 2454-2458
104. Tuttle JV, Tisdale M, Krenitsky TA: Purine 2′-deoxy-2′- fluororibosides as antiinfluenza virus agents. J Med Chem 1993; 36: 119-125
105. Furuta Y, Takahashi K, Kuno-Maekawa M, et al: Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 2005; 49: 981-986
106. Sidwell RW, Barnard DL, Day CW, et al: Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother 2007; 51: 845-851
107. Furuta Y, Takahashi K, Shiraki K, et al: T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 2009; 82: 95-102
108. Elbashir SM, Harborth J, Lendeckel W, et al: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-498
109. Ge Q, McManus MT, Nguyen T, et al: RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc Natl Acad Sci USA 2003; 100: 2718-2723
110. Ge Q, Filip L, Bai A, et al: Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci U S A 2004; 101: 8676-8681
111. Tompkins SM, Lo CY, Tumpey TM, et al: Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci U S A 2004; 101: 8682-8686
112. Li BJ, Tang Q, Cheng D, et al: Using siRNA in prophylactic and therapeutic regimens against SARS Coronavirus in Rhesus macaque. Nat Med 2005; 11: 944-951
113. Sawyer LA: Antibodies for the prevention and treatment of viral diseases. Antiviral Res 2000; 47: 57-77
114. Luke TC, Kilbane EM, Jackson JL, et al: Meta-analysis: Convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?. Ann Intern Med 2006; 145: 599-609
115. Zhou B, Zhong N, Guan Y: Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007; 357: 1450-1451
116. Wang H, Feng Z, Shu Y, et al: Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. Lancet 2008; 371: 1427-1434
117. Okuno Y, Matsumoto K, Isegawa Y, et al: Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with crossneutralizing activity among H1 and H2 strains. J Virol 1994; 68: 517-520
118. Palladino G, Mozdzanowska K, Washko G, et al: Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J Virol 1995; 69: 2075-2081
119. Mozdzanowska K, Feng J, Gerhard W: Virus-neutralizing activity mediated by the Fab fragment of a hemagglutinin-specific antibody is sufficient for the resolution of influenza virus infection in SCID mice. J Virol 2003; 77: 8322-8328
120. Simmons CP, Bernasconi NL, Suguitan AL, et al: Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 2007; 4: e178
121. Hanson BJ, Boon AC, Lim AP, et al: Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir Res 2006; 7: 126
122. Monto AS, Ohmit SE: Seasonal influenza vaccines: evolutions and future trends. Expert Rev Vacdnes 2009; 8: 383-389
123. Ansaldi F, Canepa P, Parodi V, et al: Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection. Vaccine 2009; 27: 3345-3348
124. Doroshenko A, Halperin SA: Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev Vaccines 2009; 8: 679-688
125. Price GE, Soboleski MR, Lo CY, et al: Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 2009; 27: 6512-6521
126. Patel A, Tran K, Gray M, et al: Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses. Vaccine 2009; 27: 3083-3089
127. Atmar RL, Keitel WA: Adjuvants for pandemic influenza vaccines. Curr Top Microbiol Immunol 2009; 333: 323-344
128. Kuiken T, Rimmelzwaan GF, Van Amerongen G, et al: Pathology of human influenza A (H5N1) virus infection in cynomolgus macaques (Macaca fascicularis). Vet Pathol 2003; 40304-40310
129. Choi YK, Nguyen TD, Ozaki H, et al: Studies of H5N1 influenza virus infection of pigs by using viruses isolated in Vietnam and Thailand in 2004. J Virol 2005; 79: 10821-10825